MLB-001 is expected to:
Reduce Addiction
Reduce Tolerance
Higher Adherence Rate
Substantial Pain Relief and Fewer Side Effects
MODERN PAIN MEDICATION IS RISKY
We Offer A Safer Alternative
MLB-001 is a novel opioid analgesic which addresses the issues of drug craving and liking by attenuating the release of dopamine and controlling pain at significantly lower doses by potentiating its analgesic effect.
MLB-001 has exceeded expectations in proof-of-concept testing. The activity of MLB-001 lasted 300% longer than morphine following BID administration.
Mindlab is made up of a world-class team of specialists and researchers.
THE SCIENCE
Synergy in Chemistry
MLB-001 combines morphine sulfate, dextromethorphan, and quinidine, at optimized concentrations, to simultaneously decrease morphine abuse liability and enhance pain control.
Mean± SEM group latency time measured using the tail flick (sec)
“MindLab’s novel product to address pain management on the battlefield would support readiness and care in future battlefield scenarios, and its team of highly qualified, experienced, and knowledgeable staff can successfully carry out the proposed project and demonstrated a clear and feasible strategy to obtain FDA approval.”
US Department of Defense
Rare Disease Opportunity with MLB-001
Multiple strategic companies involved in pain and SCD R&D trials.
Sickle Cell Disease
No drug approved for pain in SCD
Complex Regional Pain Disorder
Chronic neurological condition
Interstitial Cystitis
Chronic bladder condition
Our Research
We’ve created a novel formulation and clinical trial design, ratified by industry experts, that holds the promise of a solution to existing opioid deficiencies.
